Targeting FLT3 mutations in AML: review of current knowledge and evidence
Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several
genes are recurrently mutated, leading to new genomic classifications, predictive …
genes are recurrently mutated, leading to new genomic classifications, predictive …
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
H Döhner, E Estey, D Grimwade… - Blood, The Journal …, 2017 - ashpublications.org
The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
AE Perl, G Martinelli, JE Cortes… - … England Journal of …, 2019 - Mass Medical Soc
Background Patients with relapsed or refractory acute myeloid leukemia (AML) with
mutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to …
mutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to …
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open …
JE Cortes, S Khaled, G Martinelli, AE Perl… - The Lancet …, 2019 - thelancet.com
Background Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-
ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of …
ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of …
Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia
CM McMahon, T Ferng, J Canaani, ES Wang… - Cancer discovery, 2019 - AACR
Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in
relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however …
relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however …
A review of FLT3 inhibitors in acute myeloid leukemia
JC Zhao, S Agarwal, H Ahmad, K Amin, JP Bewersdorf… - Blood reviews, 2022 - Elsevier
FLT3 mutations are the most common genetic aberrations found in acute myeloid leukemia
(AML) and associated with poor prognosis. Since the discovery of FLT3 mutations and their …
(AML) and associated with poor prognosis. Since the discovery of FLT3 mutations and their …
Acute myeloid leukemia: a comprehensive review and 2016 update
I De Kouchkovsky, M Abdul-Hay - Blood cancer journal, 2016 - nature.com
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an
incidence of over 20 000 cases per year in the United States alone. Large chromosomal …
incidence of over 20 000 cases per year in the United States alone. Large chromosomal …
How I treat acute myeloid leukemia in the era of new drugs
CD DiNardo, AH Wei - Blood, The Journal of the American …, 2020 - ashpublications.org
The acute myeloid leukemia (AML) treatment landscape has changed substantially since
2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2 …
2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2 …
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
VE Kennedy, CC Smith - Frontiers in Oncology, 2020 - frontiersin.org
The FLT3 receptor is overexpressed on the majority of acute myeloid leukemia (AML) blasts.
Mutations in FLT3 are the most common genetic alteration in AML, identified in …
Mutations in FLT3 are the most common genetic alteration in AML, identified in …
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
AE Perl, JK Altman, J Cortes, C Smith, M Litzow… - The Lancet …, 2017 - thelancet.com
Background Internal tandem duplication mutations in FLT3 are common in acute myeloid
leukaemia and are associated with rapid relapse and short overall survival. The clinical …
leukaemia and are associated with rapid relapse and short overall survival. The clinical …